Merit Medical Systems earnings release, July 30, 2026
FOR IMMEDIATE RELEASE
MERIT MEDICAL REPORTS SECOND QUARTER 2026 RESULTS AND UPDATES FULL-YEAR 2026 GUIDANCE
Financial Highlights†
† Comparisons above are calculated for the current quarter compared with the second quarter of 2025, unless otherwise specified. Amounts stated in this release are rounded, while percentages are calculated from the underlying amounts.
* Constant currency revenue; constant currency revenue, organic; non-GAAP gross profit and margin; non-GAAP operating income and margin; non-GAAP net income; non-GAAP EPS; and free cash flow figures (used here and below) are non-GAAP financial measures. A reconciliation of these financial measures to their most directly comparable GAAP financial measures is included under the heading “Non-GAAP Financial Measures” below.
SOUTH JORDAN, Utah, July 30, 2026 -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer and marketer of healthcare technology, today announced financial results for the three and six-month periods ended June 30, 2026.
“Merit delivered second quarter financial results that exceeded the high end of our expectations, driven primarily by 9% organic, constant currency revenue growth, excluding the impact of a strategic divestiture,” said Martha G. Aronson, Merit’s President and CEO. “We experienced improving revenue growth trends across our global business in Q2, as expected, with notable strength in sales to customers in the U.S. which increased 10% year-over-year, well ahead of our expectations. We also delivered improvement in both our non-GAAP operating margin and our non-GAAP earnings per share, which increased by 140 basis points and 18%, respectively, year-over-year.”¹
Ms. Aronson continued: “We have increased our 2026 revenue and non-GAAP earnings per share guidance to reflect the stronger-than-expected results over the first half of 2026 and remain confident in our team’s ability to execute, with attractive constant currency growth, improving profitability, and solid cash flow generation this year. Our team remains focused on delivering our Continued Growth Initiative financial targets for the three-year period ending December 31, 2026, and, in parallel, we are developing our longer-term strategic plan focused on identifying opportunities to better position the company for sustainable growth, enhanced profitability and value creation for our shareholders.”
Merit’s revenue by product category for the three and six-month periods ended June 30, 2026 and 2025 was as follows (unaudited; in thousands, except for percentages):
²
Financial Summary:
GAAP gross margin was 51.4%, compared to 48.2% for the second quarter of 2025. Non-GAAP gross margin* was 55.8%, compared to 53.2% for the second quarter of 2025.
GAAP operating margin was 14.4%, compared to 12.3% for the second quarter of 2025. Non-GAAP operating margin* was 22.6%, compared to 21.2% for the second quarter of 2025.
GAAP net income was $38.8 million, or $0.65 per share, compared to $32.6 million, or $0.54 per share, for the second quarter of 2025. Non-GAAP net income* was $71.3 million, or $1.19 per share, compared to $61.0 million, or $1.01 per share, for the second quarter of 2025.
As of June 30, 2026, Merit had cash and cash equivalents of $448.7 million and total debt obligations of $747.5 million, compared to cash and cash equivalents of $446.4 million and total debt obligations of $747.5 million as of December 31, 2025. Merit had available borrowing capacity of approximately $697 million as of June 30, 2026.
Fiscal Year 2026 Financial Guidance
Based upon the information currently available to Merit’s management, for the twelve-month period ending December 31, 2026, absent the potential impact of trade policies and related actions implemented by the U.S. and other countries subsequent to today’s date, material acquisitions, non-recurring transactions or other factors beyond Merit’s current expectations, Merit anticipates the following financial results:
Revenue and Earnings Guidance*
*Percentage figures approximated; dollar figures may not foot due to rounding.
Financial statements
Income Statement
Revenue and Earnings Guidance*
| Updated Guidance – Year Ending – December 31, 2026 | Updated Guidance – % Change – Y/Y | Prior Guidance(2) – Year Ending – December 31, 2026 | Prior Guidance(2) – % Change – Y/Y | |
|---|---|---|---|---|
| Total Revenue | $1.631 - $1.643 billion | 8% - 8% | $1.612 - $1.634 billion | 6% - 8% |
| Non-GAAP Earnings Per Share(1) | $4.25 - $4.35 | 11% - 14% | $4.01 - $4.15 | 5% - 8% |
Income Statement
Three Months Ended — (Unaudited, in thousands except per share amounts)
| Three Months Ended – June 30, – 2026 | Three Months Ended – June 30, – 2025 | Six Months Ended – June 30, – 2026 | Six Months Ended – June 30, – 2025 | ||
|---|---|---|---|---|---|
| Net sales | 418,843 | 382,462 | 800,720 | 737,813 | |
| Cost of sales | 203,677 | 197,975 | 400,757 | 381,306 | |
| Gross profit | 215,166 | 184,487 | 399,963 | 356,507 | |
| Operating expenses: | Selling, general and administrative | 129,229 | 113,097 | 247,439 | 220,583 |
| Operating expenses: | Research and development | 25,389 | 24,367 | 47,998 | 46,845 |
| Operating expenses: | Contingent consideration expense (benefit) | 145 | 143 | -34 | 1,166 |
| Operating expenses: | Total operating expenses | 154,763 | 137,607 | 295,403 | 268,594 |
| Operating expenses: | Income from operations | 60,403 | 46,880 | 104,560 | 87,913 |
| Other income (expense): | Interest income | 3,752 | 3,761 | 7,652 | 7,551 |
| Other income (expense): | Interest expense | -12,118 | -6,775 | -18,644 | -13,343 |
| Other income (expense): | Other (expense) income — net | -723 | -487 | 11,292 | -784 |
| Other income (expense): | Total other (expense) income — net | -9,089 | -3,501 | 300 | -6,576 |
| Other income (expense): | Income before income taxes | 51,314 | 43,379 | 104,860 | 81,337 |
| Other income (expense): | Income tax expense | 12,511 | 10,798 | 25,062 | 18,609 |
| Other income (expense): | Net income | 38,803 | 32,581 | 79,798 | 62,728 |
| Earnings per common share | Basic | 0.65 | 0.55 | 1.34 | 1.06 |
| Earnings per common share | Diluted | 0.65 | 0.54 | 1.33 | 1.03 |
| Weighted average shares outstanding | Basic | 59,679 | 59,140 | 59,595 | 59,019 |
| Weighted average shares outstanding | Diluted | 60,006 | 60,611 | 60,010 | 60,945 |
Income Statement
Three Months Ended — (Unaudited, in thousands except per share amounts)
| Three Months Ended – June 30, 2026 – Pre-Tax | Three Months Ended – June 30, 2026 – Tax Impact | Three Months Ended – June 30, 2026 – After-Tax | Three Months Ended – June 30, 2026 – Per Share Impact | ||
|---|---|---|---|---|---|
| GAAP net income | 51,314 | -12,511 | 38,803 | 0.65 | |
| Cost of Sales | Amortization of intangibles | 18,718 | -4,419 | 14,299 | 0.24 |
| Operating Expenses | Contingent consideration expense | 145 | -33 | 112 | 0 |
| Operating Expenses | Amortization of intangibles | 2,496 | -589 | 1,907 | 0.03 |
| Operating Expenses | Performance-based share-based compensation (a) | 6,621 | -756 | 5,865 | 0.1 |
| Operating Expenses | Corporate restructuring (b) | 2,159 | -510 | 1,649 | 0.03 |
| Operating Expenses | Acquisition-related | 2,568 | -194 | 2,374 | 0.04 |
| Operating Expenses | Medical Device Regulation expenses (c) | 1,452 | -342 | 1,110 | 0.02 |
| Other (Income) Expense | Long-term debt costs (e) | 6,477 | -1,529 | 4,948 | 0.08 |
| Other (Income) Expense | Other non-operating loss (f) | 294 | -82 | 212 | 0 |
| Other (Income) Expense | Non-GAAP net income | 92,244 | -20,965 | 71,279 | 1.19 |
| Other (Income) Expense | Diluted shares | 60,006 |
Income Statement
Three Months Ended — (Unaudited, in thousands except per share amounts)
| Three Months Ended – June 30, 2025 – Pre-Tax | Three Months Ended – June 30, 2025 – Tax Impact | Three Months Ended – June 30, 2025 – After-Tax | Three Months Ended – June 30, 2025 – Per Share Impact | ||
|---|---|---|---|---|---|
| GAAP net income | 43,379 | -10,798 | 32,581 | 0.54 | |
| Cost of Sales | Amortization of intangibles | 18,980 | -4,485 | 14,495 | 0.24 |
| Cost of Sales | Inventory mark-up related to acquisitions | 67 | -16 | 51 | 0 |
| Operating Expenses | Contingent consideration expense | 143 | 25 | 168 | 0 |
| Operating Expenses | Amortization of intangibles | 2,543 | -601 | 1,942 | 0.03 |
| Operating Expenses | Performance-based share-based compensation (a) | 5,879 | -345 | 5,534 | 0.09 |
| Operating Expenses | Corporate restructuring (b) | 2,587 | -611 | 1,976 | 0.03 |
| Operating Expenses | Acquisition-related | 2,140 | -14 | 2,126 | 0.04 |
| Operating Expenses | Medical Device Regulation expenses (c) | 1,634 | -385 | 1,249 | 0.02 |
| Operating Expenses | Other (d) | 50 | -12 | 38 | 0 |
| Other (Income) Expense | Long-term debt costs (e) | 1,414 | -334 | 1,080 | 0.02 |
| Other (Income) Expense | Gain on disposal of business unit | -249 | -249 | 0 | |
| Other (Income) Expense | Non-GAAP net income | 78,567 | -17,576 | 60,991 | 1.01 |
| Other (Income) Expense | Diluted shares | 60,611 |
Income Statement
Six Months Ended — (Unaudited, in thousands except per share amounts)
| Six Months Ended – June 30, 2026 – Pre-Tax | Six Months Ended – June 30, 2026 – Tax Impact | Six Months Ended – June 30, 2026 – After-Tax | Six Months Ended – June 30, 2026 – Per Share Impact | ||
|---|---|---|---|---|---|
| GAAP net income | 104,860 | -25,062 | 79,798 | 1.33 | |
| Cost of Sales | Amortization of intangibles | 36,945 | -8,722 | 28,223 | 0.47 |
| Operating Expenses | Contingent consideration benefit | -34 | 5 | -29 | 0 |
| Operating Expenses | Amortization of intangibles | 4,950 | -1,168 | 3,782 | 0.06 |
| Operating Expenses | Performance-based share-based compensation (a) | 12,429 | -1,062 | 11,367 | 0.19 |
| Operating Expenses | Corporate restructuring (b) | 2,159 | -510 | 1,649 | 0.03 |
| Operating Expenses | Acquisition-related | 6,811 | -905 | 5,906 | 0.1 |
| Operating Expenses | Medical Device Regulation expenses (c) | 2,070 | -488 | 1,582 | 0.03 |
| Other (Income) Expense | Long-term debt costs (e) | 7,891 | -1,863 | 6,028 | 0.1 |
| Other (Income) Expense | Gain on disposal of business unit | -12,502 | 1,520 | -10,982 | -0.18 |
| Other (Income) Expense | Other non-operating loss (f) | 825 | -207 | 618 | 0.01 |
| Other (Income) Expense | Non-GAAP net income | 166,404 | -38,462 | 127,942 | 2.13 |
Income Statement
Six Months Ended — (Unaudited, in thousands except per share amounts)
| Six Months Ended – June 30, 2025 – Pre-Tax | Six Months Ended – June 30, 2025 – Tax Impact | Six Months Ended – June 30, 2025 – After-Tax | Six Months Ended – June 30, 2025 – Per Share Impact | ||
|---|---|---|---|---|---|
| GAAP net income | 81,337 | -18,609 | 62,728 | 1.03 | |
| Cost of Sales | Amortization of intangibles | 36,586 | -8,645 | 27,941 | 0.46 |
| Cost of Sales | Inventory mark-up related to acquisitions | 67 | -16 | 51 | 0 |
| Operating Expenses | Contingent consideration expense | 1,166 | 34 | 1,200 | 0.02 |
| Operating Expenses | Amortization of intangibles | 4,937 | -1,167 | 3,770 | 0.06 |
| Operating Expenses | Performance-based share-based compensation (a) | 10,653 | -931 | 9,722 | 0.16 |
| Operating Expenses | Corporate restructuring (b) | 2,587 | -611 | 1,976 | 0.03 |
| Operating Expenses | Acquisition-related | 2,156 | -18 | 2,138 | 0.04 |
| Operating Expenses | Medical Device Regulation expenses (c) | 3,228 | -762 | 2,466 | 0.04 |
| Operating Expenses | Other (d) | 29 | -7 | 22 | 0 |
| Other (Income) Expense | Long-term debt costs (e) | 2,828 | -668 | 2,160 | 0.04 |
| Other (Income) Expense | Gain on disposal of business unit | -249 | -249 | 0 | |
| Other (Income) Expense | Non-GAAP net income | 145,325 | -31,400 | 113,925 | 1.87 |
| Other (Income) Expense | Diluted shares | 60,945 |
Income Statement
Three Months Ended — (Unaudited, in thousands except percentages)
| Three Months Ended – June 30, 2026 – Amounts | Three Months Ended – June 30, 2026 – % Sales | Three Months Ended – June 30, 2025 – Amounts | Three Months Ended – June 30, 2025 – % Sales | Six Months Ended – June 30, 2026 – Amounts | Six Months Ended – June 30, 2026 – % Sales | Six Months Ended – June 30, 2025 – Amounts | Six Months Ended – June 30, 2025 – % Sales | ||
|---|---|---|---|---|---|---|---|---|---|
| Net Sales as Reported | 418,843 | 382,462 | 800,720 | 737,813 | |||||
| GAAP Operating Income | 60,403 | 14.4% | 46,880 | 12.3% | 104,560 | 13.1% | 87,913 | 11.9% | |
| Cost of Sales | Amortization of intangibles | 18,718 | 4.5% | 18,980 | 5.0% | 36,945 | 4.6% | 36,586 | 5.0% |
| Cost of Sales | Inventory mark-up related to acquisitions | 67 | 0.0% | 67 | 0.0% | ||||
| Operating Expenses | Contingent consideration expense (benefit) | 145 | 0.0% | 143 | 0.0% | -34 | -0.0% | 1,166 | 0.2% |
| Operating Expenses | Amortization of intangibles | 2,496 | 0.6% | 2,543 | 0.7% | 4,950 | 0.6% | 4,937 | 0.7% |
| Operating Expenses | Performance-based share-based compensation (a) | 6,621 | 1.6% | 5,879 | 1.5% | 12,429 | 1.6% | 10,653 | 1.4% |
| Operating Expenses | Corporate restructuring (b) | 2,159 | 0.5% | 2,587 | 0.7% | 2,159 | 0.3% | 2,587 | 0.4% |
| Operating Expenses | Acquisition-related | 2,568 | 0.6% | 2,140 | 0.6% | 6,811 | 0.9% | 2,156 | 0.3% |
| Operating Expenses | Medical Device Regulation expenses (c) | 1,452 | 0.3% | 1,634 | 0.4% | 2,070 | 0.3% | 3,228 | 0.4% |
| Operating Expenses | Other (d) | 50 | 0.0% | 29 | 0.0% | ||||
| Operating Expenses | Non-GAAP Operating Income | 94,562 | 22.6% | 80,903 | 21.2% | 169,890 | 21.2% | 149,322 | 20.2% |
Balance Sheet
December 31, — (in thousands)
| June 30, – 2026 – (Unaudited) | December 31, – 2025 | ||
|---|---|---|---|
| Current Assets | Cash and cash equivalents | 448,699 | 446,404 |
| Current Assets | Trade receivables, net | 224,237 | 203,710 |
| Current Assets | Other receivables | 23,960 | 17,773 |
| Current Assets | Inventories | 374,112 | 333,705 |
| Current Assets | Prepaid expenses and other assets | 33,496 | 31,493 |
| Current Assets | Prepaid income taxes | 5,033 | 4,941 |
| Current Assets | Income tax refund receivables | 2,701 | 2,128 |
| Current Assets | Total current assets | 1,112,238 | 1,040,154 |
| Current Assets | Property and equipment, net | 436,749 | 428,401 |
| Current Assets | Intangible assets, net | 612,026 | 537,654 |
| Current Assets | Goodwill | 539,772 | 506,837 |
| Current Assets | Deferred income tax assets | 7,200 | 7,049 |
| Current Assets | Operating lease right-of-use assets | 83,776 | 87,600 |
| Current Assets | Other assets | 71,859 | 78,227 |
| Current Assets | Total Assets | 2,863,620 | 2,685,922 |
| Current Liabilities | Trade payables | 70,737 | 60,551 |
| Current Liabilities | Accrued expenses | 172,185 | 159,486 |
| Current Liabilities | Current operating lease liabilities | 10,921 | 10,876 |
| Current Liabilities | Income taxes payable | 11,090 | 8,851 |
| Current Liabilities | Total current liabilities | 264,933 | 239,764 |
| Current Liabilities | Long-term debt | 736,258 | 734,038 |
| Current Liabilities | Deferred income tax liabilities | 39,704 | 19,665 |
| Current Liabilities | Liabilities related to unrecognized tax benefits | 2,248 | 2,248 |
| Current Liabilities | Deferred compensation payable | 19,297 | 17,542 |
| Current Liabilities | Deferred credits | 1,347 | 1,398 |
| Current Liabilities | Long-term operating lease liabilities | 72,942 | 76,658 |
| Current Liabilities | Other long-term obligations | 47,087 | 10,306 |
| Current Liabilities | Total liabilities | 1,183,816 | 1,101,619 |
| Stockholders' Equity | Common stock | 783,892 | 763,909 |
| Stockholders' Equity | Retained earnings | 903,828 | 824,030 |
| Stockholders' Equity | Accumulated other comprehensive loss | -7,916 | -3,636 |
| Stockholders' Equity | Total stockholders' equity | 1,679,804 | 1,584,303 |
| Stockholders' Equity | Total Liabilities and Stockholders' Equity | 2,863,620 | 2,685,922 |
Cash Flow
Six Months Ended — (Unaudited, in thousands)
| Six Months Ended – June 30, – 2026 | Six Months Ended – June 30, – 2025 | ||
|---|---|---|---|
| CASH FLOWS FROM OPERATING ACTIVITIES: | Net income | 79,798 | 62,728 |
| Adjustments to reconcile net income to net cash provided by operating activities: | Depreciation and amortization | 61,538 | 60,313 |
| Adjustments to reconcile net income to net cash provided by operating activities: | Gain on disposition of a business | -12,557 | -249 |
| Adjustments to reconcile net income to net cash provided by operating activities: | Amortization of right-of-use operating lease assets | 5,779 | 5,766 |
Full release
(1) Merit’s non-GAAP earnings per share reflect the dilutive impact of its 3.00% Convertible Senior Notes due 2029 (the “Convertible Notes”) calculated using the if-converted method of approximately $0.03 per share for the year ending December 31, 2026. Any offsetting impacts of the capped call associated with the Convertible Notes are not considered.
(2) “Prior Guidance” reflects Merit’s full-year 2026 financial guidance, previously introduced on April 30, 2026.
Merit does not provide guidance for GAAP reported financial measures (other than revenue) or a reconciliation of forward-looking non-GAAP financial measures to the most directly comparable GAAP reported financial measures (other than revenue) because Merit is unable to predict with reasonable certainty the financial impact of various items which could impact Merit’s future financial results, such as expenses attributable to acquisitions or other extraordinary transactions, non-cash expenses related to amortization or write-off of previously acquired tangible and intangible assets, certain employee termination benefits, performance-based stock compensation expenses, expenses resulting from non-ordinary course litigation or administrative proceedings and resulting settlements, governmental proceedings, and changes in governmental or industry regulations. These items are uncertain, depend on various factors, and could have a material impact on GAAP reported results for the guidance period. For the same reasons, Merit is unable to address the significance of the unavailable information, which could be material to future results. Specifically, Merit is not, without unreasonable effort, able to reasonably predict the amount and impact of these items and Merit believes inclusion of the most comparable GAAP financial measure, and a reconciliation of these forward-looking non-GAAP measures to their GAAP counterparts could be confusing to investors or cause undue reliance.
Merit’s financial guidance for the year ending December 31, 2026 is subject to risks and uncertainties identified in this release and Merit’s filings with the SEC. This guidance is based on information and estimates available to Merit as of July 30, 2026. Should known or unknown risks or uncertainties materialize or should underlying assumptions prove inaccurate, actual results will likely vary, and could vary materially, from past results and those anticipated, estimated or projected.³
CONFERENCE CALL
As previously announced, Merit will hold its investor conference call today, Thursday, July 30, 2026, at 4:30 p.m., Eastern Time, to discuss its results for the second quarter and provide an operational update.
To access the conference call, please pre-register using the following link.
Registrants will receive confirmation with dial-in details.
A live webcast and slide deck will also be available at merit.com.